World Antibody Drug Conjugates Market 2017-2030 - Featuring Over 500 Companies with Interviews from Market Leaders

DUBLIN, November 17, 2017 /PRNewswire/ --

The "Antibody Drug Conjugates Market (4th Edition) 2017-2030" report has been added to Research and Markets' offering.

The Antibody Drug Conjugates Market (4th Edition), 2017-2030' report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market.

The field has captured the interest of several drug developers, both small and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 10% of candidate therapies are presently in advanced stages (phase II and above); we anticipate the market to witness continued growth in the next 5-10 years.

Since the first approval of MYLOTARG in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS in 2011 and KADCYLA in 2013, there was a temporary, but evident, decline in the popularity of ADCs.

This was attributed to the fact that no new ADC candidates were approved after 2013 and the focus had shifted to other novel therapies, such as immune checkpoint inhibitors and T-cell therapies. However, the recent approval of BESPONSA and re-approval of MYLOTARG has renewed the interest of stakeholders in the domain. This growing popularity and potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 1,395 patents in 2009 to 10,208 patents in the first half of 2017.

While there are close to 200 ADCs in clinical / preclinical stages of development, the field is currently going through a gradual transition. The industry is shifting from relying on conventional technologies to newer approaches for generating ADCs. This transition has paved way for several well-funded start-ups, which offer novel conjugation approaches, more potent warheads and modified linker technologies.

In addition, the ADCs are now being evaluated in combination with several other novel therapies, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies.

Key Topics Covered:

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines